Searched for
ARIPIPRAZOLE
Is Elon Musk Hypomanic? Here's all about the lesser-known but serious mental illnessDr. Drew Pinsky suggests Elon Musk may exhibit hypomania, a milder form of mania, citing his intense work ethic, impulsive behavior, and er...- Unichem Labs rises 5% as Porinju’s PMS firm increases stakeThe company last month had received Abbreviated New Drug Application approval from the US Food and Drug Administration (USFDA) for Aripipra...
- Biggest gainers & losers of the day: Neogen rallied 15%, Vodafone zooms 13%The 30-share pack Sensex soared 764.83 points or 1.31 per cent to close at 57,696.46. Its broader peer Nifty50 gained 204.95 points or 1.19...
- Indian drug firms recall products in US marketWhile Lupin and Marksans Pharma are recalling diabetes drug, Aurobindo and Alembic are recalling psychiatric medication in the US market.
- Zydus Cadila gets USFDA nod for antipsychotic drugThe group has more than 243 approvals, and so far filed over 330 abbreviated new drug applications (ANDAs) since it started filings in 2003...
- We expect domestic business to grow at 15%: S Ramesh, LupinI expect the price erosion to continue in America in the first two quarters at least for the current year before it stabilises around 8-10%.
- Alembic Pharma slips 3% as Q3 net tumblesMD Pranav Amin said: "Our base business in the US is doing well. We will continue to invest in R&D for future growth and have spent Rs 117 ...
- Alembic Pharma Q3 net profit at Rs 86.55 croreConsolidated total income from operations during the quarter under review also fell to Rs 777.03 crore from Rs 930.89 crore a year ago.
- USFDA nods to Indian drugs up 84% in 1 yearInterestingly, the growth came during the period when biggies like Sun Pharma and Dr Reddy's had reduced filings from their plants due to c...
- Despite being on rough end, annual report from US FDA’s OGD shows Indian firms won key approvals in 2015The annual report released by the FDA’s OGD shows Indian companies have won some key approvals in the world’s biggest pharmaceuticals marke...
- Alembic Pharma Q3 net profit zooms four-fold to Rs 269 croreAlembic Pharmaceuticals reported nearly 4-fold jump in its consolidated net profit to Rs 269.49 crore for the quarter ended December 31.
- Aurobindo gains on USFDA final nod for anti-psychotic tabletsShares of Aurobindo Pharma climbed five per cent today as the company has received final approval from the US health regulator FDA to manuf...
- Cipla set to buy American business of Hetero Drugs for $550 millionPeople close to the transaction said Cipla will buy Invagen and Camber, Hetero’s wholly owned subsidiary, for about $550 million.
- Hetero buy will boost Cipla's US ops in next 2-3 years; hold stock @ target of Rs 755: Praful Bohra, Religare"Cipla's portfolio is of a commodity generics type; so this will definitely place it in a strong position in terms of product pipeline in t...
- Fifteen stocks in focus in Thursday morning tradeIndian markets are expected to trade in a range. Here is a list of fifteen stocks which are likely to be in focus today.
- Cadila stock touches 52 week high after gettting USFDA approval for two generic drugsAccording to pharma analyst, the company would continue to witness jump in its stock prices as it is bullish on getting FDA approval for it...
- Zydus Cadila gets USFDA nod for schizophrenia drugThe company got a tentative approval for aripiprazole orally disintegrating tabs in the strengths of 10 mg, 15 mg, 20 mg and 30 mg.
Load More
